PURPOSE: Proliferative vitreoretinopathy (PVR) occurs in approximately 10% of patients after retinal detachment. PVR results from a multiphase process that leads to an aberrant wound-healing strategy with contractile cellular forces and tractional retinal detachment (TRD). Epithelial membrane protein (EMP) 2 controls cell surface expression and function of integrin isoforms associated with cellular contraction in many cell types. Since EMP2 is highly expressed in retinal pigment epithelium, this study investigates the role of EMP2 in collagen gel contraction. METHODS: EMP2 expression was recombinantly modified in the ARPE-19 cell line. Cell surface integrin expression was assessed by flow cytometry. Collagen gel contraction was assessed by using an in vitro assay and the percentage of contraction was quantified. Proliferation and migration were measured by BrdU incorporation and a wound-healing assay, respectively. Cellular invasion was investigated with polycarbonate membranes coated with collagen. RESULTS: EMP2 expression levels correlated positively with the ability to contract collagen gels. Compared with wild-type ARPE-19 cells, the cells with increased EMP2 expression exhibited enhanced contraction (P = 0.02), and decreased EMP2 expression concomitantly resulted in decreased contraction (P = 0.002). EMP2 overexpression resulted in reduced proliferation, migration, and integrin alpha1 and alpha2 integrin expression. EMP2 overexpression was associated with a 70% increase in FAK activation (P = 0.0003) and relative resistance of gel contraction to inhibitors of FAK/Src activation. CONCLUSIONS: ARPE-19-mediated collagen gel contraction is a multistep process that requires integrin ligation and activation of the FAK/Src complex. EMP2 positively modulates collagen gel contraction by ARPE-19 cells through increased FAK activation.
PURPOSE: Proliferative vitreoretinopathy (PVR) occurs in approximately 10% of patients after retinal detachment. PVR results from a multiphase process that leads to an aberrant wound-healing strategy with contractile cellular forces and tractional retinal detachment (TRD). Epithelial membrane protein (EMP) 2 controls cell surface expression and function of integrin isoforms associated with cellular contraction in many cell types. Since EMP2 is highly expressed in retinal pigment epithelium, this study investigates the role of EMP2 in collagen gel contraction. METHODS:EMP2 expression was recombinantly modified in the ARPE-19 cell line. Cell surface integrin expression was assessed by flow cytometry. Collagen gel contraction was assessed by using an in vitro assay and the percentage of contraction was quantified. Proliferation and migration were measured by BrdU incorporation and a wound-healing assay, respectively. Cellular invasion was investigated with polycarbonate membranes coated with collagen. RESULTS:EMP2 expression levels correlated positively with the ability to contract collagen gels. Compared with wild-type ARPE-19 cells, the cells with increased EMP2 expression exhibited enhanced contraction (P = 0.02), and decreased EMP2 expression concomitantly resulted in decreased contraction (P = 0.002). EMP2 overexpression resulted in reduced proliferation, migration, and integrin alpha1 and alpha2 integrin expression. EMP2 overexpression was associated with a 70% increase in FAK activation (P = 0.0003) and relative resistance of gel contraction to inhibitors of FAK/Src activation. CONCLUSIONS: ARPE-19-mediated collagen gel contraction is a multistep process that requires integrin ligation and activation of the FAK/Src complex. EMP2 positively modulates collagen gel contraction by ARPE-19 cells through increased FAK activation.
Authors: Madhuri Wadehra; Ashley Forbes; Natasha Pushkarna; Lee Goodglick; Lynn K Gordon; Carmen J Williams; Jonathan Braun Journal: Dev Biol Date: 2005-10-10 Impact factor: 3.582
Authors: Madhuri Wadehra; Molina Dayal; Monica Mainigi; Teri Ord; Ramaswamy Iyer; Jonathan Braun; Carmen J Williams Journal: Dev Biol Date: 2006-02-20 Impact factor: 3.582
Authors: Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon Journal: Exp Eye Res Date: 2012-06-19 Impact factor: 3.467
Authors: Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2009-06-03 Impact factor: 4.799
Authors: Shawn A Morales; David G Telander; Deanna Leon; Krisztina Forward; Jonathan Braun; Madhuri Wadehra; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2013-03-28 Impact factor: 4.799
Authors: Maoyong Fu; Erin L Maresh; Robert A Soslow; Mohammad Alavi; Vei Mah; Qin Zhou; Alexia Iasonos; Lee Goodglick; Lynn K Gordon; Jonathan Braun; Madhuri Wadehra Journal: Clin Cancer Res Date: 2010-08-01 Impact factor: 12.531
Authors: Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra Journal: Mol Cancer Ther Date: 2014-01-21 Impact factor: 6.261
Authors: Shawn A Morales; David Telander; Lucia Notterpek; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2011-07-23 Impact factor: 4.799